VAG
FHTX icon

VisionPoint Advisory Group’s Foghorn Therapeutics FHTX Stock Holding History

VisionPoint Advisory Group’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-210
Closed -$1.21K – 426
2024
Q2 		$1.21K Hold
210
– – ﹤0.01% 709
2024
Q1 		$1.41K Hold
210
– – ﹤0.01% 707
2023
Q4 		$1.35K Hold
210
– – ﹤0.01% 657
2023
Q3 		$1.05K Hold
210
– – ﹤0.01% 611
2023
Q2 		$1.48K Buy
+210
New +$1.47K ﹤0.01% 490

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VisionPoint Advisory Group's FHTX Position: Q3 2024 in Review

VisionPoint Advisory Group sold out of Foghorn Therapeutics (FHTX) in Q3 2024, closing a stake of 210 shares — an estimated $1.21K sold.

VisionPoint Advisory Group first reported a position in FHTX in Q2 2023 and held it in 5 quarters. The position peaked at $1.48K in Q2 2023. 79 funds tracked by Wall St. Rank hold FHTX as of Q3 2024.

  • VisionPoint Advisory Group reported no remaining Foghorn Therapeutics position as of Q3 2024 after selling out during the quarter.
  • VisionPoint Advisory Group sold 210 Foghorn Therapeutics shares in Q3 2024, an estimated $1.21K.
  • VisionPoint Advisory Group first reported a position in Foghorn Therapeutics in Q2 2023 and held it in 5 quarters.
  • VisionPoint Advisory Group's Foghorn Therapeutics position peaked at $1.48K in Q2 2023.
  • 79 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q3 2024.

Based on VisionPoint Advisory Group's 13F filing for Q3 2024, filed 15 Oct 2024.